DoD Tuberous Sclerosis Complex Idea Development Award
The summary for the DoD Tuberous Sclerosis Complex Idea Development Award grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
DoD Tuberous Sclerosis Complex Idea Development Award: The IDA promotes new ideas that are in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative, high-risk/potentially high-reward research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.
The following are important aspects of the Idea Development Award:
1. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative.
2. Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care.
3. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, should be included.
All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (http://www.nature.com/nature/journal/ v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment X, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.elsevier.com/__data/promis_misc/ 622936arrive_guidelines.pdf.
The following are important aspects of the Idea Development Award:
1. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative.
2. Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care.
3. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, should be included.
All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (http://www.nature.com/nature/journal/ v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment X, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.elsevier.com/__data/promis_misc/ 622936arrive_guidelines.pdf.
Federal Grant Title: | DoD Tuberous Sclerosis Complex Idea Development Award |
Federal Agency Name: | Dept of the Army USAMRAA |
Grant Categories: | Science and Technology |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | W81XWH-15-TSCRP-IDA |
Type of Funding: | Cooperative Agreement, Grant |
CFDA Numbers: | 12.420 |
CFDA Descriptions: | Military Medical Research and Development |
Current Application Deadline: | Jul 27, 2015 |
Original Application Deadline: | Jul 27, 2015 |
Posted Date: | May 6, 2015 |
Creation Date: | May 6, 2015 |
Archive Date: | Aug 26, 2015 |
Total Program Funding: | $3,360,000 |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | 4 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- Grant Announcement Contact
- CDMRP Help Desk
Phone: 301-682-5507
CDMRP Help Desk
Dept. of the Army -- USAMRAA 301-619-7144 - Similar Government Grants
- • DoD Ovarian Cancer, Ovarian Cancer Clinical Trial Academy - Early-Career Investigator Awar...
- • DoD Ovarian Cancer Ovarian Cancer Academy - Early-Career Investigator Award
- • DoD Peer Reviewed Medical, Impact Award
- • DoD Peer Reviewed Medical, Lifestyle and Behavioral Health Interventions Research Award
- • DoD Peer Reviewed Medical, Discovery Award
- • FY2006 Deployed War Fighter Protection Research Program
- • Department of Defense (DOD) Fiscal Year 2003 (FY03) Breast Cancer Research Program (BCRP)C...
- • Department of Defense (DOD) Fiscal Year 2004 (FY04) Breast Cancer Research Program (BCRP) ...
- More Grants from the Dept of the Army USAMRAA
- • DoD Ovarian Cancer Ovarian Cancer Academy - Early-Career Investigator Award
- • DoD Peer Reviewed Medical, Impact Award
- • DoD Peer Reviewed Medical, Technology/Therapeutic Development Award